NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

August 15, 2022 6:50 AM EDT

Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET

RADNOR, Pa., Aug. 15, 2022  /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022 and provided a business and clinical update.

... More